Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: the eagle who wrote (759)	3/4/1998 8:58:00 PM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

A friend called investor relations at MGI Pharma today and this is what he found out: They finally got the last patient treated at 14mg/m2. Results expected later this month. The second phase I study at Madison is now at a dose of 11mg/m2. They have not selected a tumor type for Phase II. Between the NCI and MGI, more than one tumor type will be studied. MGI's tumor type selection is completely independent of the choice made by the NCI. MGI has significant input into the NCI's study but MGI's phase II study is independent of the NCI. They expect that the Euro partner will want to participate in the phase II trials. (more evidence that they expect a Euro partner before or shortly after the start of Phase II) One reason the company is doing their own phase II trial is the NCI is characterized as being slow. But the primary reason for MGI's study, independent of the NCI, is as follows (repeated 3x): THE SELECTION OF THE TUMOR TYPE BY MGI IS GOING TO BE BASED UPON WHAT THEY WILL BE ABLE TO GET TO MARKET THE FASTEST. His commentary: This may mean leukemia because its easier to study (patient's blood samples are rapidly analyzed), it may mean a tumor type considered difficult to treat, or it may mean a tumor type were patients are easy to find. David